Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
© 2024. The Author(s)..
BACKGROUND: This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti-vascular endothelial growth factor (VEGF) monotherapy.
METHODS: Post hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12.
MAIN OUTCOME MEASURE: association between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA).
RESULTS: In both trials (HARBOR, N = 36; READ-3, N = 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (-2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of -9.0 (-22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters.
CONCLUSIONS: Higher IL-6 AH concentrations may predict suboptimal visual responses to anti-VEGF monotherapy in patients with nAMD/DMO.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Eye (London, England) - (2024) vom: 15. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sepah, Yasir Jamal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41433-024-03015-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371114519 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371114519 | ||
| 003 | DE-627 | ||
| 005 | 20240416233539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41433-024-03015-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371114519 | ||
| 035 | |a (NLM)38622330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sepah, Yasir Jamal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti-vascular endothelial growth factor (VEGF) monotherapy | ||
| 520 | |a METHODS: Post hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12 | ||
| 520 | |a MAIN OUTCOME MEASURE: association between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA) | ||
| 520 | |a RESULTS: In both trials (HARBOR, N = 36; READ-3, N = 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (-2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of -9.0 (-22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters | ||
| 520 | |a CONCLUSIONS: Higher IL-6 AH concentrations may predict suboptimal visual responses to anti-VEGF monotherapy in patients with nAMD/DMO | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Do, Diana V |e verfasserin |4 aut | |
| 700 | 1 | |a Mesquida, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Bann-Mo |e verfasserin |4 aut | |
| 700 | 1 | |a Blotner, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Afridi, Rubbia |e verfasserin |4 aut | |
| 700 | 1 | |a Halim, Muhammad Sohail |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Kyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wakshull, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Fauser, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Stoilov, Ivaylo |e verfasserin |4 aut | |
| 700 | 1 | |a Dong Nguyen, Quan |e verfasserin |4 aut | |
| 700 | 0 | |a HARBOR |e verfasserin |4 aut | |
| 700 | 0 | |a READ-3 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, P |e investigator |4 oth | |
| 700 | 1 | |a Alfaro, D V |c 3rd |e investigator |4 oth | |
| 700 | 1 | |a Antoszyk, A |e investigator |4 oth | |
| 700 | 1 | |a Antworth, M |e investigator |4 oth | |
| 700 | 1 | |a Baker, B |e investigator |4 oth | |
| 700 | 1 | |a Baker, C |e investigator |4 oth | |
| 700 | 1 | |a Balles, M |e investigator |4 oth | |
| 700 | 1 | |a Boyer, D |e investigator |4 oth | |
| 700 | 1 | |a Bridges, W |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Brown, D M |e investigator |4 oth | |
| 700 | 1 | |a Busbee, B |e investigator |4 oth | |
| 700 | 1 | |a Busquets, M |e investigator |4 oth | |
| 700 | 1 | |a Chan, C |e investigator |4 oth | |
| 700 | 1 | |a Chaudhry, N |e investigator |4 oth | |
| 700 | 1 | |a Chen, S |e investigator |4 oth | |
| 700 | 1 | |a Christoforidis, J |e investigator |4 oth | |
| 700 | 1 | |a Ciulla, T |e investigator |4 oth | |
| 700 | 1 | |a Clark, W L |e investigator |4 oth | |
| 700 | 1 | |a Cleland, T |e investigator |4 oth | |
| 700 | 1 | |a Connor, T |e investigator |4 oth | |
| 700 | 1 | |a Daccache, A |e investigator |4 oth | |
| 700 | 1 | |a Dessouki, A |e investigator |4 oth | |
| 700 | 1 | |a Diddie, K |e investigator |4 oth | |
| 700 | 1 | |a Doft, B |e investigator |4 oth | |
| 700 | 1 | |a Dreyer, R |e investigator |4 oth | |
| 700 | 1 | |a Faber, D W |e investigator |4 oth | |
| 700 | 1 | |a Feiner, L |e investigator |4 oth | |
| 700 | 1 | |a Feldman, R |e investigator |4 oth | |
| 700 | 1 | |a Ferrone, P |e investigator |4 oth | |
| 700 | 1 | |a Fox, G |e investigator |4 oth | |
| 700 | 1 | |a Foxman, S |e investigator |4 oth | |
| 700 | 1 | |a Frenkel, R |e investigator |4 oth | |
| 700 | 1 | |a Fung, A |e investigator |4 oth | |
| 700 | 1 | |a Gallemore, R |e investigator |4 oth | |
| 700 | 1 | |a Ghuman, T |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, V |e investigator |4 oth | |
| 700 | 1 | |a Gordon, A |e investigator |4 oth | |
| 700 | 1 | |a Gordon, C |e investigator |4 oth | |
| 700 | 1 | |a Gupta, S |e investigator |4 oth | |
| 700 | 1 | |a Hariprasad, S |e investigator |4 oth | |
| 700 | 1 | |a Heier, J |e investigator |4 oth | |
| 700 | 1 | |a Ho, A |e investigator |4 oth | |
| 700 | 1 | |a Holmes, D |e investigator |4 oth | |
| 700 | 1 | |a Huang, J |e investigator |4 oth | |
| 700 | 1 | |a Hubschman, J P |e investigator |4 oth | |
| 700 | 1 | |a Hudson, H |e investigator |4 oth | |
| 700 | 1 | |a Ie, D |e investigator |4 oth | |
| 700 | 1 | |a Johnson, R |e investigator |4 oth | |
| 700 | 1 | |a Katz, R |e investigator |4 oth | |
| 700 | 1 | |a Kiss, S |e investigator |4 oth | |
| 700 | 1 | |a Kitchens, J |e investigator |4 oth | |
| 700 | 1 | |a Kokame, G |e investigator |4 oth | |
| 700 | 1 | |a Lit, E |e investigator |4 oth | |
| 700 | 1 | |a Liu, M |e investigator |4 oth | |
| 700 | 1 | |a Luu, J K |e investigator |4 oth | |
| 700 | 1 | |a MacCumber, M |e investigator |4 oth | |
| 700 | 1 | |a Madreperla, S |e investigator |4 oth | |
| 700 | 1 | |a Marcus, D |e investigator |4 oth | |
| 700 | 1 | |a Martidis, A |e investigator |4 oth | |
| 700 | 1 | |a Martinez, J |e investigator |4 oth | |
| 700 | 1 | |a Michels, M |e investigator |4 oth | |
| 700 | 1 | |a Miller, D |e investigator |4 oth | |
| 700 | 1 | |a Morse, L |e investigator |4 oth | |
| 700 | 1 | |a Nasir, M |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Q |e investigator |4 oth | |
| 700 | 1 | |a Oliver, S |e investigator |4 oth | |
| 700 | 1 | |a Olsen, K |e investigator |4 oth | |
| 700 | 1 | |a Patel, S |e investigator |4 oth | |
| 700 | 1 | |a Pavan, P |e investigator |4 oth | |
| 700 | 1 | |a Pearlman, J |e investigator |4 oth | |
| 700 | 1 | |a Prenner, J |e investigator |4 oth | |
| 700 | 1 | |a Regillo, C |e investigator |4 oth | |
| 700 | 1 | |a Reichel, E |e investigator |4 oth | |
| 700 | 1 | |a Rosa, R |e investigator |4 oth | |
| 700 | 1 | |a Rose, S |e investigator |4 oth | |
| 700 | 1 | |a Sadda, S |e investigator |4 oth | |
| 700 | 1 | |a Samuel, M |e investigator |4 oth | |
| 700 | 1 | |a Singerman, L |e investigator |4 oth | |
| 700 | 1 | |a Singer, M |e investigator |4 oth | |
| 700 | 1 | |a Singh, R |e investigator |4 oth | |
| 700 | 1 | |a Stoller, G |e investigator |4 oth | |
| 700 | 1 | |a Suner, I |e investigator |4 oth | |
| 700 | 1 | |a Tabassian, A |e investigator |4 oth | |
| 700 | 1 | |a Taney, B |e investigator |4 oth | |
| 700 | 1 | |a Thach, A |e investigator |4 oth | |
| 700 | 1 | |a Thomas, M |e investigator |4 oth | |
| 700 | 1 | |a Tolentino, M |e investigator |4 oth | |
| 700 | 1 | |a Tom, D |e investigator |4 oth | |
| 700 | 1 | |a Tornambe, P |e investigator |4 oth | |
| 700 | 1 | |a Torti, R |e investigator |4 oth | |
| 700 | 1 | |a Truong, S |e investigator |4 oth | |
| 700 | 1 | |a Verstraeten, T |e investigator |4 oth | |
| 700 | 1 | |a Wagner, A |e investigator |4 oth | |
| 700 | 1 | |a Wald, K |e investigator |4 oth | |
| 700 | 1 | |a Weber, P |e investigator |4 oth | |
| 700 | 1 | |a Weishaar, P |e investigator |4 oth | |
| 700 | 1 | |a Wieland, M |e investigator |4 oth | |
| 700 | 1 | |a Williams, D |e investigator |4 oth | |
| 700 | 1 | |a Wong, T |e investigator |4 oth | |
| 700 | 1 | |a Wood, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Eye (London, England) |d 1995 |g (2024) vom: 15. Apr. |w (DE-627)NLM012628646 |x 1476-5454 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41433-024-03015-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 | ||